Malignancy and rheumatoid arthritis

被引:32
|
作者
Askling J. [1 ]
机构
[1] Clinical Epidemiology Unit M9:01, Department of Medicine Solna, Karolinska University Hospital Solna
关键词
Rheumatoid Arthritis; Cancer Risk; Abatacept; Cancer Occurrence; Rheumatoid Arthritis Treatment;
D O I
10.1007/s11926-007-0067-1
中图分类号
学科分类号
摘要
The occurrence of cancer is not an infrequent event in patients with rheumatoid arthritis (RA). Indeed, following diagnosis of RA at a typical age (55 years), one in five patients will be diagnosed with cancer. In the vast majority of such cases, the cancer has nothing to do with RA or its treatment; rather, it represents the "background" risk applicable to all humans. In some cases, the cancer occurs as a result of factors also associated with the risk of developing RA (eg, smoking), even though no direct link exists between the cancer and the RA. In a fraction of cases, however, the cancer is causally associated with the RA disease or its treatments. This review summarizes our current understanding of the occurrence of cancer in RA, possible links to RA disease and to traditional and newer RA treatments. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:421 / 426
页数:5
相关论文
共 50 条
  • [21] Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis
    Katelynn M. Wilton
    Eric L. Matteson
    Rheumatology and Therapy, 2017, 4 : 333 - 347
  • [22] Malignancy validation in a United States registry of rheumatoid arthritis patients
    Fisher, Mark C.
    Furer, Victoria
    Hochberg, Marc C.
    Greenberg, Jeffrey D.
    Kremer, Joel M.
    Curtis, Jeff R.
    Reed, George
    Harrold, Leslie
    Solomon, Daniel H.
    BMC MUSCULOSKELETAL DISORDERS, 2012, 13
  • [23] Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
    Jeon, Chan Hong
    JOURNAL OF RHEUMATIC DISEASES, 2022, 29 (04): : 191 - 192
  • [24] LYMPHOPROLIFERATIVE MALIGNANCY IN RHEUMATOID-ARTHRITIS - A STUDY OF 20 CASES
    SYMMONS, DPM
    AHERN, M
    BACON, PA
    HAWKINS, CF
    AMLOT, PL
    JONES, EL
    PRIOR, P
    SCOTT, DL
    ANNALS OF THE RHEUMATIC DISEASES, 1984, 43 (02) : 132 - 135
  • [25] Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis
    Khan, Omair
    Baqir, Syed Mujtaba
    Naeem, Azka
    Khan, Muhammad Hashim
    Shyam, Tharun
    Slobodyanyuk, Kseniya
    Slobodnick, Anastasia
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2853 - 2856
  • [26] Cryptogenic Organizing Pneumonia Mimicking Malignancy in a Patient with Rheumatoid Arthritis
    Konsta, Maria
    Bournia, Vassiliki-Kalliopi
    Alexandrou, Paraskevi
    Iliopoulos, Alexios
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (09) : 2007 - 2008
  • [27] PREVALENCE AND CLINICAL CHARACTERISTICS OF MALIGNANCY IN SEROPOSITIVE RHEUMATOID ARTHRITIS PATIENTS
    Park, J.
    Lee, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1131 - 1131
  • [28] Malignancy validation in a United States registry of rheumatoid arthritis patients
    Mark C Fisher
    Victoria Furer
    Marc C Hochberg
    Jeffrey D Greenberg
    Joel M Kremer
    Jeff R Curtis
    George Reed
    Leslie Harrold
    Daniel H Solomon
    BMC Musculoskeletal Disorders, 13
  • [29] Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy
    Kunishita, Yosuke
    Ichikawa, Kento
    Uzawa, Yuji
    Mitsuhashi, Masaki
    Yoshioka, Yuji
    Okubo, Tadanobu
    Nagaoka, Shouhei
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2023, 15
  • [30] Antimalarial drugs and malignancy: no evidence of a protective effect in rheumatoid arthritis
    Bernatsky, S.
    Clarke, A.
    Suissa, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) : 277 - 278